# A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.

> **NCT07375758** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 130 (estimated)

## Conditions studied

- Immunoglobulin A Nephropathy

## Interventions

- **DRUG:** MIL116
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT07375758
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-05
- **Primary completion:** 2028-06
- **Final completion:** 2029-06
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07375758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07375758, "A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07375758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*